Cargando…

Pharmacological therapy and blood pressure control in primary health care sites in China: data from 254,848 hypertensive patients

BACKGROUND: Studies on pharmacological therapy and blood pressure (BP) control in primary health care sites of China are limited. We aimed to investigate drug use and compliance as well as compare BP control between pharmacological therapies for lowering BP in hypertensive population serviced by the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Lei, Chen, Xiaorong, Chen, Bo, Liu, Longjian, Sun, Xiaohui, Zou, Yuewei, Liu, Hongjian, Guo, Hui, Zhang, Jian, Ma, Jixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188195/
https://www.ncbi.nlm.nih.gov/pubmed/30349394
http://dx.doi.org/10.2147/CLEP.S172567
_version_ 1783363179255955456
author Hou, Lei
Chen, Xiaorong
Chen, Bo
Liu, Longjian
Sun, Xiaohui
Zou, Yuewei
Liu, Hongjian
Guo, Hui
Zhang, Jian
Ma, Jixiang
author_facet Hou, Lei
Chen, Xiaorong
Chen, Bo
Liu, Longjian
Sun, Xiaohui
Zou, Yuewei
Liu, Hongjian
Guo, Hui
Zhang, Jian
Ma, Jixiang
author_sort Hou, Lei
collection PubMed
description BACKGROUND: Studies on pharmacological therapy and blood pressure (BP) control in primary health care sites of China are limited. We aimed to investigate drug use and compliance as well as compare BP control between pharmacological therapies for lowering BP in hypertensive population serviced by these sites. METHODS: This is a 1-year cohort study using electronic health care records from the National Primary Public Health Services of China. For patients with antihypertensive drugs at the first follow-up, we defined compliance with treatment as a continued treatment with the same specified class of agents at next three follow-ups. In those with compliance, BP control was defined as systolic BP <140 mmHg and diastolic BP <90 mmHg in four follow-ups within 1 year. RESULTS: Primary health care sites of four areas managed 254,848 hypertensive patients aged ≥35 years. At the first follow-up, 50.2% of the patients took medicines for lowering BP. In those, calcium channel antagonist monotherapy was the most common medicine in urban areas (57.1% vs 15.6% in rural areas, P<0.001); however, the most common one was single-pill combinations including diuretics and non-first-line drugs in rural areas (34.4% vs 10.7% in urban areas, P<0.001). Compliance was 79.9% and 53.2% for single- and multiple-pill combinations in first-line drugs; this rate was 69.5% and 45.0% in regimens combined with non-first-line drugs, respectively. Compared with calcium channel antagonists, diuretics monotherapy increased the overall BP control by 11% (risk ratio, 1.11; 95% confidence interval, 1.08 to 1.13), but it was used in few patients (3.3%); first-line multiple-pill combinations significantly decreased BP control by 20% to 28% in three less urbanized areas, but a similar BP control was achieved in the highly urbanized area. CONCLUSION: Our study indicated that drug use such as diuretics could be strengthened in primary health care sites and combined therapy may be improved particularly in less urbanized areas.
format Online
Article
Text
id pubmed-6188195
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61881952018-10-22 Pharmacological therapy and blood pressure control in primary health care sites in China: data from 254,848 hypertensive patients Hou, Lei Chen, Xiaorong Chen, Bo Liu, Longjian Sun, Xiaohui Zou, Yuewei Liu, Hongjian Guo, Hui Zhang, Jian Ma, Jixiang Clin Epidemiol Original Research BACKGROUND: Studies on pharmacological therapy and blood pressure (BP) control in primary health care sites of China are limited. We aimed to investigate drug use and compliance as well as compare BP control between pharmacological therapies for lowering BP in hypertensive population serviced by these sites. METHODS: This is a 1-year cohort study using electronic health care records from the National Primary Public Health Services of China. For patients with antihypertensive drugs at the first follow-up, we defined compliance with treatment as a continued treatment with the same specified class of agents at next three follow-ups. In those with compliance, BP control was defined as systolic BP <140 mmHg and diastolic BP <90 mmHg in four follow-ups within 1 year. RESULTS: Primary health care sites of four areas managed 254,848 hypertensive patients aged ≥35 years. At the first follow-up, 50.2% of the patients took medicines for lowering BP. In those, calcium channel antagonist monotherapy was the most common medicine in urban areas (57.1% vs 15.6% in rural areas, P<0.001); however, the most common one was single-pill combinations including diuretics and non-first-line drugs in rural areas (34.4% vs 10.7% in urban areas, P<0.001). Compliance was 79.9% and 53.2% for single- and multiple-pill combinations in first-line drugs; this rate was 69.5% and 45.0% in regimens combined with non-first-line drugs, respectively. Compared with calcium channel antagonists, diuretics monotherapy increased the overall BP control by 11% (risk ratio, 1.11; 95% confidence interval, 1.08 to 1.13), but it was used in few patients (3.3%); first-line multiple-pill combinations significantly decreased BP control by 20% to 28% in three less urbanized areas, but a similar BP control was achieved in the highly urbanized area. CONCLUSION: Our study indicated that drug use such as diuretics could be strengthened in primary health care sites and combined therapy may be improved particularly in less urbanized areas. Dove Medical Press 2018-10-11 /pmc/articles/PMC6188195/ /pubmed/30349394 http://dx.doi.org/10.2147/CLEP.S172567 Text en © 2018 Hou et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hou, Lei
Chen, Xiaorong
Chen, Bo
Liu, Longjian
Sun, Xiaohui
Zou, Yuewei
Liu, Hongjian
Guo, Hui
Zhang, Jian
Ma, Jixiang
Pharmacological therapy and blood pressure control in primary health care sites in China: data from 254,848 hypertensive patients
title Pharmacological therapy and blood pressure control in primary health care sites in China: data from 254,848 hypertensive patients
title_full Pharmacological therapy and blood pressure control in primary health care sites in China: data from 254,848 hypertensive patients
title_fullStr Pharmacological therapy and blood pressure control in primary health care sites in China: data from 254,848 hypertensive patients
title_full_unstemmed Pharmacological therapy and blood pressure control in primary health care sites in China: data from 254,848 hypertensive patients
title_short Pharmacological therapy and blood pressure control in primary health care sites in China: data from 254,848 hypertensive patients
title_sort pharmacological therapy and blood pressure control in primary health care sites in china: data from 254,848 hypertensive patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188195/
https://www.ncbi.nlm.nih.gov/pubmed/30349394
http://dx.doi.org/10.2147/CLEP.S172567
work_keys_str_mv AT houlei pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients
AT chenxiaorong pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients
AT chenbo pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients
AT liulongjian pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients
AT sunxiaohui pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients
AT zouyuewei pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients
AT liuhongjian pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients
AT guohui pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients
AT zhangjian pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients
AT majixiang pharmacologicaltherapyandbloodpressurecontrolinprimaryhealthcaresitesinchinadatafrom254848hypertensivepatients